Currently, CYP2C19 testing is commissioned through the Genomics Medicine Service only for patients expected to start on mavacamten.
Please see our rare and inherited disease pages for further information.
CYP2C19 testing in line with NICE DG59 [CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack] is currently being assessed for wider implementation by NHS England and NICE.
This provisional guidance is provided to support clinicians interested in providing CYP2C19 testing for patients under their care.